ClearPoint Neuro, Inc. Appoints Ellisa Cholapranee as General Counsel

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

March 24, 2021

ClearPoint Neuro, Inc. is a global therapy-enabling platform company providing navigation and delivery to the brain. Today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021.

Ellisa Cholapranee will report directly to Joe Burnett, ClearPoint Neuro’s Chief Executive Officer, and serve as a member of the Company’s senior leadership team.

“Ellisa is a tremendous addition to our capable and growing leadership team,” commented Joe Burnett, President, and CEO of ClearPoint Neuro. “Not only does Ellisa offer the broad experience in compliance, contracting, and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight having worked extensively as a partner to the pharma industry will enhance communication and efficiency, both in signing new gene therapy and stem cell partners, as well as broaching more sophisticated risk-sharing agreements with our collaborators.”

Ellisa Cholapranee brings to the Company almost a decade of experience advising companies in the life science and medical device sectors on legal, business, and compliance issues. Before joining the Company, she was Senior Legal Counsel for the cardiovascular devices division at Philips.

Prior to that, Ms. Cholapranee served as Senior Corporate Counsel at MilliporeSigma, a global life science company focused on providing solutions to pharmaceutical companies in every step of the biotech production chain, from research to drug manufacturing. She also has several years’ experience in the corporate and financial services departments of leading law firms in Boston and Chicago, where she counseled clients in the areas of corporate law, public offerings, mergers and acquisitions, and venture capital. Ms. Cholapranee holds a Bachelor of Science in Mathematics from Carnegie Mellon University and a J.D. from the Northwestern University Pritzker School of Law.

“I am thrilled to join ClearPoint at such an exciting phase of the Company’s growth,” stated Ellisa Cholapranee. “ClearPoint’s technology and team are truly impressive. I look forward to helping build upon the many successes of the Company.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.